康方生物(09926):依沃西对比帕博利珠用于一线治疗PD -L1表达阳性NSCLC的HARMONi-2研究期中分析达到OS关键次要终点 具有统计学显著和临床获益
Last Update:
3 9 月, 2026
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.